Nurses stage protest seeking regularisation of services, equal pay
Nurses affiliated to The Tamil Nadu Nurses Empowerment Association staged a demonstration in Chennai on Thursday, urging the State government to regularise the services of all nurses on consolidated pay, and to implement a court order granting equal pay for equal work.
About 250 nurses from across the State took part in the protest. They urged the DMK government to fulfil its election promise to regularise the services of all nurses on consolidated pay. Of the 15,000 nurses who were recruited through the Medical Services Recruitment Board (MRB) on consolidated pay, around 8,000 have been regularised so far.
The nurses started off with a consolidated pay of ₹7,700 in 2015 and, after several protests, their pay was increased to ₹14,000 in 2018. In 2021, it was increased to ₹18,000 with an annual increment of 5%, according to N. Subin, general secretary of the association.
Nurses on regular posts get a salary of nearly ₹60,000 in the city, while those on consolidated pay receive ₹18,000. The court order on equal pay for equal work should be implemented by the government. Similarly, another judgment granting maternity leave and benefits to nurses on consolidated pay should be implemented, he added.
The association demanded that permanent posts of nurses should be created in accordance with the patient strength, following the recommendations of the National Medical Commission and Indian Public Health Standards. 'While new district headquarters hospitals are being established, no new posts of nurses are being created. Instead, nurses from other institutions are being diverted,' Mr. Subin said.
All the nurses who worked during the COVID-19 pandemic, and whose services were terminated, should be reinstated, the association said.
Among other demands, the association demanded the restoring of nursing superintendent grade 3 posts, and fixing of salaries for promotions at seven, 14, 20, and 25 years for nurses.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?
What's Behind the FDA's New Warning? Who Faces the Highest Risk? Live Events What's Changing in the Vaccine Labels? What's the FDA Doing Next? FAQs (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The US Food and Drug Administration (FDA) has warned that COVID-19 vaccines, which are manufactured by Pfizer and Moderna, have the potential for cardiac risks, as per a warnings were first proposed in letters, which were sent to both companies in April, providing additional information about the potential risks of myocarditis and/or pericarditis associated with the two vaccines, as reported by the Cardiovascular Business report. Myocarditis and pericarditis have the possibility of leading to long-term heart damage, according to the READ: Meet Trapit Bansal, Meta's new AI superintelligence team hire - Is Meta poaching top talent from OpenAI? FDA's latest update covers Pfizer's Comirnaty vaccine and Moderna's Spikevax vaccine, while both companies had mentioned text about myocarditis and pericarditis in the labelling for these vaccines since 2021, but the FDA wanted more information added to these warnings that specifically mentions the increased risks for young men, as per the Cardiovascular Business READ: After Canada, now US: College graduates face the toughest job market in decades – what's gone wrong? According to the Cardiovascular Business report, the new labeling for both the vaccines is now required to include the following text, as per FDA's latest update:"Based on analyses of commercial health insurance claims data from inpatient and outpatient settings, the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age," as quoted in the label should also include, "Follow-up information on cardiovascular outcomes in hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis is available from a longitudinal retrospective observational study. Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their diagnosis. In this study, at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common. The clinical and prognostic significance of these CMR findings is not known," as quoted by the Cardiovascular Business READ: Top economist warns: US faces a crisis worse than recession — here's what could be coming While, FDA has also emphasised that it plans to keep tracking the safety of COVID-19 vaccines from now on, as per the agency said, 'Continuous monitoring and assessment of the safety of all vaccines, including the mRNA COVID-19 vaccines, is an FDA priority and we remain committed to informing the public when we learn new information about these vaccines,' adding, 'In addition, as part of the approvals of Comirnaty and Spikevax, each manufacturer is required by FDA to conduct a study to assess if there are long-term heart effects in people who have had myocarditis after receiving an mRNA COVID-19 vaccine. These studies are underway,' quoted by the Cardiovascular Business FDA wants the public to have clearer information about rare heart-related risks linked to COVID-19 mRNA vaccines, especially for young men, as per the Cardiovascular Business the FDA continues to support their use, but these warnings are about rare side effects, as per the Cardiovascular Business report.
Time of India
an hour ago
- Time of India
FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?
The US Food and Drug Administration (FDA) has warned that COVID-19 vaccines, which are manufactured by Pfizer and Moderna, have the potential for cardiac risks, as per a report. What's Behind the FDA's New Warning? These warnings were first proposed in letters, which were sent to both companies in April, providing additional information about the potential risks of myocarditis and/or pericarditis associated with the two vaccines, as reported by the Cardiovascular Business report. Myocarditis and pericarditis have the possibility of leading to long-term heart damage, according to the report. ALSO READ: Meet Trapit Bansal, Meta's new AI superintelligence team hire - Is Meta poaching top talent from OpenAI? by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo Who Faces the Highest Risk? FDA's latest update covers Pfizer's Comirnaty vaccine and Moderna's Spikevax vaccine, while both companies had mentioned text about myocarditis and pericarditis in the labelling for these vaccines since 2021, but the FDA wanted more information added to these warnings that specifically mentions the increased risks for young men, as per the Cardiovascular Business report. ALSO READ: After Canada, now US: College graduates face the toughest job market in decades – what's gone wrong? Live Events What's Changing in the Vaccine Labels? According to the Cardiovascular Business report, the new labeling for both the vaccines is now required to include the following text, as per FDA's latest update: "Based on analyses of commercial health insurance claims data from inpatient and outpatient settings, the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age," as quoted in the report. The label should also include, "Follow-up information on cardiovascular outcomes in hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis is available from a longitudinal retrospective observational study. Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their diagnosis. In this study, at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common. The clinical and prognostic significance of these CMR findings is not known," as quoted by the Cardiovascular Business report. ALSO READ: Top economist warns: US faces a crisis worse than recession — here's what could be coming What's the FDA Doing Next? While, FDA has also emphasised that it plans to keep tracking the safety of COVID-19 vaccines from now on, as per the report. The agency said, 'Continuous monitoring and assessment of the safety of all vaccines, including the mRNA COVID-19 vaccines, is an FDA priority and we remain committed to informing the public when we learn new information about these vaccines,' adding, 'In addition, as part of the approvals of Comirnaty and Spikevax, each manufacturer is required by FDA to conduct a study to assess if there are long-term heart effects in people who have had myocarditis after receiving an mRNA COVID-19 vaccine. These studies are underway,' quoted by the Cardiovascular Business report. FAQs Why is the FDA updating warnings now? The FDA wants the public to have clearer information about rare heart-related risks linked to COVID-19 mRNA vaccines, especially for young men, as per the Cardiovascular Business report. Are Moderna and Pfizer vaccines still considered safe? Yes, the FDA continues to support their use, but these warnings are about rare side effects, as per the Cardiovascular Business report.
The Hindu
3 hours ago
- The Hindu
Vaccinating India: on zero-dose children
On the bright side, vaccine coverage globally, between 1980 and 2023, doubled for six diseases including measles, polio and tuberculosis. Also, at 75% globally, there has been a sharp fall in the number of zero-dose children — those who have not received the first dose of the diphtheria, tetanus, and pertussis (DTP) vaccine — during the same time period. The number of zero-dose children is a crucial performance marker and an indicator of vaccination coverage inequities. Despite increased immunisation coverage over the decades, in 2023, at 1.44 million, India, according to The Lancet, still had the second largest number of zero-dose children, and is among the eight countries with over 50% of the nearly 16 million zero-dose children globally. Most of the zero-dose children globally are in countries that are conflict-affected or with limited resources for vaccination programmes — India has neither of the two problems. However, about 23 million babies were born in 2023 in India, the highest in the world; in 2024, China, which has the second highest number of newborns globally, reported just 9.5 million newborns. Though the number of zero-dose children is staggering, when seen in the context of the number of newborns in 2023, the percentage of zero-dose children in India is 6.2%. A study in 2021 found that India had sharply reduced the percentage of zero-dose children, from 33.4% in 1992 to 10.1% in 2016. Before the COVID-19 pandemic, the number of zero-dose children was 1.4 million in 2019 but this swelled to 2.7 million in 2021 and then dropped to 1.1 million in 2022 before increasing to 1.44 million in 2023. As in the 2021 study, a large percentage of zero-dose children are in Uttar Pradesh, Bihar, Maharashtra, Rajasthan, Madhya Pradesh, and Gujarat. There is also a relatively high proportion of them in Meghalaya, Nagaland, Mizoram and Arunachal Pradesh. Over the years, the difference in zero-dose children based on gender, caste, and rural-urban status has reduced substantially. However, prevalence remains high among the poor, mothers with low education, Scheduled Tribes and Muslims. Focus is needed to immunise children in hard-to-reach tribal areas, urban slums where there is a huge migrant population, and in reducing vaccine hesitancy among Muslim households with newborn children. India has much work to do to meet WHO's Immunization Agenda 2030 (IA2030) — halving zero-dose children relative to 2019. With the number of zero-dose children in 2023 (1.44 million) only about nearly reaching the 2019 level of 1.4 million, India needs greater and sustained efforts to halve this number in the next five years.
